



Sentien Biotechnologies Appoints Dr. Pedro Huertas as Chief Medical Officer

LEXINGTON, MA, October 1, 2018 – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel cell therapies to restore balance to the immune system, today announced the appointment of Pedro Huertas, M.D. Ph.D., as its Chief Medical Officer. Dr. Huertas will join Sentien’s executive team and oversee the clinical development of Sentien’s lead product, SBI-101.

Dr. Huertas brings nearly 30 years of pharmaceutical industry experience in research and development, medical affairs, and regulatory affairs. Prior to joining Sentien, Dr. Huertas was Chief Medical Officer for Eloxx Pharmaceuticals, a company focused on rare and ultra-rare genetic diseases. His prior experience includes clinically-focused positions with big pharmaceutical (Pfizer, Genzyme), small biotechnology (ExSAR Corporation, Amicus Therapeutics, Novazyme), and cell therapy companies (Ocata, StemCells, Inc.). Dr. Huertas is a graduate of Stanford University (M.S., Biochemistry), Harvard University (Ph.D., Cell and Developmental Biology), Harvard Medical School (M.D.), and MIT Sloan School of Management (M.S., Management). He also trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.

“Dr. Huertas’ extensive clinical development experience and particularly his expertise in cell therapy and the rare disease space makes him an ideal fit for Sentien,” said Sentien CEO, Brian Miller. “His strategic leadership will be critical for Sentien as we complete our first clinical trial of SBI-101 in patients with acute kidney injury and advance our novel cell therapy platform to treat other systemic inflammatory conditions.”

“I am very excited to be joining Sentien Biotechnologies as Chief Medical Officer,” said Dr. Huertas. “The potential of Sentien’s technology to treat systemic inflammatory disease is far-reaching and I look forward to leading the clinical development efforts to bring this innovative new treatment to patients with few therapeutic options.”

About Sentien Biotechnologies

Sentien Biotechnologies, Inc. is a privately-owned, clinical-stage company developing novel cell therapies to restore balance to the immune system. Sentien is developing innovative

blood conditioning systems to treat a wide range of systemic inflammatory diseases. Sentien's lead product, SBI-101, is designed to allow for controlled, sustained delivery of mesenchymal stromal cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic factors that are unattainable by direct injection.

SBI-101 is the first product application of Sentien's platform blood conditioning technology, currently being evaluated in a Phase 1/2 study in patients with acute kidney injury.

For more information, please visit www.sentienbiotech.com.

###

Media Contact:

Brian Miller, CEO
Sentien Biotechnologies, Inc.
(781) 361-9031
info@sentienbiotech.com